LGBTQ Community Archives in Small Urban Centers: Reflections on Community and University Partnerships to Build Awareness of the Lehigh Valley’s Rich LGBTQ History from AIDS Activism to Anti-Discrimination Legislation

Too frequently regional LGBTQ history outside of major metropolises is not a major focus either in university curriculum or for financially strapped local non-profit organizations as they provide essential direct services to our communities. Even as the late twentieth and early twenty-first century have ushered in a new focus on local archival projects, regional organizations often struggle to find funding for local historical projects while universities provide LGBTQ studies courses that center activism in NYC, Los Angeles, or San Francsico, marches in Washington, D.C., and the value of subcultural spaces on the coasts. As scholars have argued in the past decade, literary critics and historians need to focus more attention on LGBTQ activism, cultural production, and community formations outside of major urban centers. For university faculty, staff, and archivists, we have the opportunity to address this need by partnering with regional LGBTQ organizations, using our resources to help build strong local archives, and working with community members to shape narratives about LGBTQ history that engage with national movements while also addressing the nuances of activist work in various cultural contexts. This article addresses how community center leaders, archivists, faculty, and students in Allentown, PA have collaborated to meet these challenges by discussing three impactful archival projects: F.A.C.T. (Fighting AIDS Continuously Together) public history courses, an exhibit titled “Pride Guides and the Early Years of Lehigh Valley Pride Festivals,” and the Lehigh Valley LGBT Community Oral History Project. As we provide details about these projects, we trace the value of centering regional AIDS activism, pride celebrations, and struggles for anti-discrimination legislation for our regional LGBTQ community and our students. We argue that courses, exhibits, and oral history collection not only produce regional connectivity to national political projects and strategies, but also build stronger understanding of the import of local activism for promoting equity at the civic and state level. Beyond understanding the historical trajectory of regional activism, archival work and exhibitions bring diverse young people, elders, and those in the middle of life together who may not have met otherwise to reflect on our history and to imagine our future. The process of incorporating students, organizational leaders, and archivists in shared historical projects and narratives formation builds new networks for meeting urgent present-day needs

Framing our Future: The Development of the Science and Technology Framework for Information Literacy in Higher Education

Poster Presentation given at STS ALA Annual conference

Phase 2 Study of Weekly Bortezomib in Mantle Cell and Follicular Lymphoma

Twice-weekly bortezomib has proven activity in mantle cell (MCL) and indolent lymphomas. This study explored a weekly schedule of bortezomib in follicular lymphoma (FL) and MCL. Although weekly bortezomib was better tolerated, the overall response rate (ORR) was inferior (18% vs. 50%, p = 0.02) with no complete remissions (CR) (compared with 18% CR for the twice-weekly schedule). Progression-free survival (PFS) was not different. The weekly schedule of bortezomib was less toxic, but yielded fewer and lower quality responses than twice-weekly bortezomib. Given the similar PFS, the weekly schedule may still be appropriate for some patients

Phase II-I-II Study of Two Different Doses and Schedules of Pralatrexate, a High-Affinity Substrate for the Reduced Folate Carrier, in Patients With Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies

PurposeTo determine the maximum-tolerated dose (MTD) and efficacy of pralatrexate in patients with lymphoma.Patients and MethodsPralatrexate, initially given at a dose of 135 mg/m2on an every-other-week basis, was associated with stomatitis. A redesigned, weekly phase I/II study established an MTD of 30 mg/m2weekly for six weeks every 7 weeks. Patients were required to have relapsed/refractory disease, an absolute neutrophil greater than 1,000/μL, and a platelet count greater than 50,000/μL for the first dose of any cycle.ResultsThe every-other-week, phase II experience was associated with an increased risk of stomatitis and hematologic toxicity. On a weekly schedule, the MTD was 30 mg/m2weekly for 6 weeks every 7 weeks. This schedule modification resulted in a 50% reduction in the major hematologic toxicities and abrogation of the grades 3 to 4 stomatitis. Stomatitis was associated with elevated homocysteine and methylmalonic acid, which were reduced by folate and vitamin B12 supplementation. Of 48 assessable patients, the overall response rate was 31% (26% by intention to treat), including 17% who experienced complete remission (CR). When analyzed by lineage, the overall response rates were 10% and 54% in patients with B- and T-cell lymphomas, respectively. All eight patients who experienced CR had T-cell lymphoma, and four of the six patients with a partial remission were positron emission tomography negative. The duration of responses ranged from 3 to 26 months.ConclusionPralatrexate has significant single-agent activity in patients with relapsed/refractory T-cell lymphoma